These findings are consistent with the 2025 Consensus Recommendations for the Management of Neurosarcoidosis which strongly favor anti-TNF-α inhibitor therapies, particularly IFX, as the preferred steroid-sparing agent during induction [36]. Here, TNF is linked to neurosarcoidosis.